Patent Score Card: Kyle Bass Gets 17 IPR Reviews Granted, 14 Denied
This article was originally published in The Pink Sheet Daily
Executive Summary
Bass wins review of four Acorda patents based on SEC registration filing; Patent Trial and Appeal Board declines to institute inter partes review of Enbrel patent and Insys' Subsys patents but okays trial on Juxtapid patents.
You may also be interested in...
Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.
PTO Affirms Shire’s Lialda Patent; First Decision In Kyle Bass IPR Case
Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.